Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data
- 1 March 2010
- journal article
- review article
- Published by Future Science Ltd in Bioanalysis
- Vol. 2 (3), 429-440
- https://doi.org/10.4155/bio.10.6
Abstract
The background to human microdosing or Phase 0 studies is reviewed, focusing particularly on the information that such studies can provide in the context of exploratory clinical development. Examples are provided of the microdose-validation studies known as the Consortium for Resourcing and Evaluating AMS Microdosing trial and EU Microdosing AMS Partnership Programme, which demonstrated that there was good dose proportionality between microdose and pharmacological dose pharmacokinetics. When microdosing was applied to ten development drugs, it was found that all ten molecules showed dose proportionality between the microdose and the pharmacological dose. The majority of microdose studies have used accelerator mass spectrometry (AMS) analysis and only these studies that are considered here; AMS provides information on all metabolites, even if these are minor. There is now sufficient scientific data to justify microdose studies being routinely conducted as part of the drug-development process.Keywords
This publication has 29 references indexed in Scilit:
- Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and inductionExpert Opinion on Drug Metabolism & Toxicology, 2006
- How many genomics targets can a portfolio afford?Drug Discovery Today, 2005
- Environmental and chemical carcinogenesisSeminars in Cancer Biology, 2004
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- R&D Costs and Returns by Therapeutic CategoryDrug Information Journal, 2004
- The formation of AFB1-macromolecular adducts in rats and humans at dietary levels of exposureFood and Chemical Toxicology, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- ADMET in silico modelling: towards prediction paradise?Nature Reviews Drug Discovery, 2003
- The druggable genomeNature Reviews Drug Discovery, 2002
- Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low doseInternational Journal of Cancer, 1999